商品编号


AG-CR1-3595-M500



品牌


Adipogen



公司


Adipogen



公司分类


Cancer



Size

500 mg


商品信息


More Information



Product Details



Synonyms

PLC



Product Type

Chemical



Properties



Formula

C
10
H
19
NO
4
. HCl



MW

217.3 . 36.5



CAS

119793-66-7



Source/Host Chemicals

Synthetic.



Purity Chemicals

≥98% (NMR)



Appearance

White to off-white solid.



Solubility

Soluble in water, methanol, ethanol, DMSO or dimethyl formamide.



InChi Key

KTFMPDDJYRFWQE-DDWIOCJRSA-N



Shipping and Handling



Shipping

AMBIENT



Short Term Storage

+4°C



Long Term Storage

-20°C



Handling Advice

Hygroscopic.



Use/St
ABI
lity

Stable for at least 2 years after receipt when stored at -20°C.



Documents



MSD
S


Download PDF



Product Specification Sheet



Datasheet


Download PDF






Naturally occurring carnitine derivative formed by carnitine acetyltransferase during β-oxidation of uneven chain fatty acids, with high affinity for muscular carnitine transferase. Increases cellular carnitine content, allowing free fatty acid transport into the mitochondria [1, 5].

Stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activity [1, 2].

Important for mitochondrial metabolism and energy regulation. Regulates the metabolism of both carbohydrates and lipids, le
ADI
ng to an increase of ATP generation [9, 11].

Selectively inhibits
in vitro
and
ex vivo
platelet-activating factor (PAF) synthesis from human neutrophils [3].

Antioxidant. Shows free r
ADI
cal scavenging activity [4].

Decreases the expression of induc
IBL
e nitric oxide synthase (iNOS/NOS II) and NADPH-oxidase 4-mediated reactive oxygen species production in human umbilical vascular endothelial cells [7].

Shows beneficial cardiovascular effects. Improves body weight, food intake,
ADI
posity and insulin resistance in Type 2 diabetes [5, 6, 8-10].

Stimulates endothelial nitric oxide (eNOS/NOS III) and increased NO production, via AMPK/Src-mediated signaling that leads to activation of PI3 kinase and Akt [6, 12].



Product References

Changes in skeletal muscle histology and metabolism in patients undergoing exercise deconditioning: effect of propionyl-L-carnitine: G. Brevetti, et al.; Muscle Nerve
20,
1115 (1997)

Propionyl-L-carnitine: L.R. Wiseman & R.N. Brogden; Drugs Aging
12,
243 (1998) (Review)

Inhibition of platelet-activating factor synthesis in human neutrophils and platelets by propionyl-L-carnitine: M. Triggiani, et al.; Biochem. Pharmacol.
58,
1341 (1999)

L-propionyl-carnitine as superoxide scavenger, antioxidant, and DNA cleavage protector: A. Vanella, et al.; Cell Biol. Toxicol.
16,
99 (2000)

Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review: R. Ferrari, et al.; Ann. N. Y. Acad. Sci.
1033,
79 (2004) (Review)

Oral supplementation of propionyl-l-carnitine reduces body weight and hyperinsulinaemia in obese Zucker rats: C. Mingorance, et al.; Br. J. Nutr.
102,
1145 (2009)

Propionyl-L-carnitine improves postischemic blood flow recovery and arteriogenetic revascularization and reduces endothelial NADPH-oxidase 4-mediated superoxide production: M.A. Stasi, et al.; Arterioscler. Thromb. Vasc. Biol.
30,
426 (2010)

Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders: C. Mingorance, et al.; Vasc. Health Risk Manag.
7,
169 (2011)

Pharmacological effects and clinical applications of propionyl-L-carnitine: C. Mingorance, et al.; Nutr. Rev.
69,
279 (2011) (Review)

Propionyl-L-carnitine corrects metabolic and cardiovascular alterations in diet-induced obese mice and improves liver respiratory chain activity: C. Mingorance, et al.; PLoS One
7,
e34268 (2012)

Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine: S.M. Marcovina, et al.; Transl. Res.
161,
73 (2013)

Propionyl-L-carnitine induces eNOS activation and nitric oxide synthesis in endothelial cells via PI3 and Akt kinases: W.H. Ning & K. Zhao; Vascul. Pharmacol.
59,
76 (2013)